BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 21784052)

  • 1. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
    Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
    Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow miR-10a overexpression is associated with genetic events but not affects clinical outcome in acute myeloid leukemia.
    Zhang TJ; Guo H; Zhou JD; Li XX; Zhang W; Ma JC; Wen XM; Yao XY; Lin J; Qian J
    Pathol Res Pract; 2018 Jan; 214(1):169-173. PubMed ID: 29254789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
    Wynendaele J; Böhnke A; Leucci E; Nielsen SJ; Lambertz I; Hammer S; Sbrzesny N; Kubitza D; Wolf A; Gradhand E; Balschun K; Braicu I; Sehouli J; Darb-Esfahani S; Denkert C; Thomssen C; Hauptmann S; Lund A; Marine JC; Bartel F
    Cancer Res; 2010 Dec; 70(23):9641-9. PubMed ID: 21084273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia.
    Pigazzi M; Manara E; Baron E; Basso G
    Cancer Res; 2009 Mar; 69(6):2471-8. PubMed ID: 19258499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
    Ries C; Loher F; Zang C; Ismair MG; Petrides PE
    Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of specific microRNA and their targets in acute myeloid leukemia.
    Cammarata G; Augugliaro L; Salemi D; Agueli C; La Rosa M; Dagnino L; Civiletto G; Messana F; Marfia A; Bica MG; Cascio L; Floridia PM; Mineo AM; Russo M; Fabbiano F; Santoro A
    Am J Hematol; 2010 May; 85(5):331-9. PubMed ID: 20425795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth.
    Agirre X; Jiménez-Velasco A; San José-Enériz E; Garate L; Bandrés E; Cordeu L; Aparicio O; Saez B; Navarro G; Vilas-Zornoza A; Pérez-Roger I; García-Foncillas J; Torres A; Heiniger A; Calasanz MJ; Fortes P; Román-Gómez J; Prósper F
    Mol Cancer Res; 2008 Dec; 6(12):1830-40. PubMed ID: 19074828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
    Russ AC; Sander S; Lück SC; Lang KM; Bauer M; Rücker FG; Kestler HA; Schlenk RF; Döhner H; Holzmann K; Döhner K; Bullinger L
    Haematologica; 2011 Dec; 96(12):1783-91. PubMed ID: 21880628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis.
    Larramendy ML; Niini T; Elonen E; Nagy B; Ollila J; Vihinen M; Knuutila S
    Haematologica; 2002 Jun; 87(6):569-77. PubMed ID: 12031912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia.
    van Stijn A; Kok A; van der Pol MA; Feller N; Roemen GM; Westra AH; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2003 Apr; 17(4):780-6. PubMed ID: 12682637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
    Xiang L; Li M; Liu Y; Cen J; Chen Z; Zhen X; Xie X; Cao X; Gu W
    Ann Hematol; 2013 Aug; 92(8):1063-9. PubMed ID: 23515710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer.
    Tsang WP; Ng EK; Ng SS; Jin H; Yu J; Sung JJ; Kwok TT
    Carcinogenesis; 2010 Mar; 31(3):350-8. PubMed ID: 19926638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia.
    Noguera NI; Ammatuna E; Zangrilli D; Lavorgna S; Divona M; Buccisano F; Amadori S; Mecucci C; Falini B; Lo-Coco F
    Leukemia; 2005 Aug; 19(8):1479-82. PubMed ID: 15973451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.
    Gao XN; Lin J; Li YH; Gao L; Wang XR; Wang W; Kang HY; Yan GT; Wang LL; Yu L
    Oncogene; 2011 Aug; 30(31):3416-28. PubMed ID: 21399664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.
    Seyyedi SS; Soleimani M; Yaghmaie M; Ajami M; Ajami M; Pourbeyranvand S; Alimoghaddam K; Akrami SM
    Tumour Biol; 2016 Apr; 37(4):4841-7. PubMed ID: 26526573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia.
    Oppliger Leibundgut E; Porret NA; Bienz Muggli M; Baumgartner H; Dahlhaus M; Baerlocher GM
    Ann Hematol; 2013 Jan; 92(2):173-7. PubMed ID: 23161387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-21 is overexpressed in NPM1-mutant acute myeloid leukemias.
    Riccioni R; Lulli V; Castelli G; Biffoni M; Tiberio R; Pelosi E; Lo-Coco F; Testa U
    Leuk Res; 2015 Feb; 39(2):221-8. PubMed ID: 25543261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.